UK Alzheimer’s Disease Drugs Market Report 2022 to 2030

UK Alzheimer’s Disease Drugs Market Analysis

$ 3999

The UK Alzheimer’s disease drugs market was valued at $401 Mn in 2022 and is estimated to expand at a CAGR of 6.42% from 2022-30 and will reach $660 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are AbbVie, AstraZeneca, Accord Healthcare, Aesica Queenborough, Allen & Hanburys, Biogen, Daiichi Sankyo Company, Eisai Co., Eli Lilly and Company, Johnson and Johnson, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, Ono Pharmaceutical Co., Pfizer and Teva Pharmaceutical among others.

ID: IN10GBPH006 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Nandini Shah

Buy Now

UK Alzheimer’s Disease Drugs Market Executive Summary

The UK Alzheimer’s Disease Drugs market was valued at $401 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 6.42% from 2022 to 2030 and will reach $660 Mn in 2030. Alzheimer's disease is a degenerative neurological ailment that impairs the ability of the brain to operate normally. Alzheimer's disease symptoms often begin with modest memory loss and difficulties with language and communication. Patients may experience progressively severe memory loss, confusion, and trouble with daily activities as the condition develops. Alzheimer's disease is eventually fatal, with patients typically living 4 to 8 years after symptoms appear.

According to Alzheimer's Society, 2019, there were approximately 850,000 persons in the UK with dementia in 2019. This equates to one in every 14 of the population aged 65 and up. At the present rate of prevalence, the UK will have almost 1.5 Mn people with dementia by 2040.

UK alzheimers disease drugs market analysis

Market Dynamics

Market Growth Drivers

Alzheimer's disease is a progressive neurological disorder that primarily affects older adults, and the prevalence of the disease is increasing globally due to the aging population. In the UK, it is estimated that around 850,000 people are living with dementia, with Alzheimer's disease being the most common form. As the number of people affected by Alzheimer's disease continues to rise, the demand for drugs to treat the disease is expected to increase as well. There has been a significant amount of research and development in the field of Alzheimer's disease, with several promising drugs in the pipeline. For example, there are ongoing clinical trials of drugs that target amyloid beta, a protein that forms plaques in the brains of people with Alzheimer's disease. If these drugs are successful, they could provide new patient treatment options and drive growth in the Alzheimer's drugs market.

The UK government has launched several initiatives aimed at improving the care and treatment of people with Alzheimer's disease. For example, the government's National Dementia Strategy aims to improve early diagnosis and access to treatment for people with dementia, including Alzheimer's disease. These initiatives could help to increase the demand for Alzheimer's drugs and drive growth in the market. There is growing awareness of Alzheimer's disease and its impact on individuals and society. This increased awareness could lead to more people seeking diagnosis and treatment for the disease, which could drive growth in the Alzheimer's drugs market.

Market Restraints

While there are several drugs available to treat Alzheimer's disease, these treatments are not effective for all patients, and there is no cure for the disease. This can be frustrating for patients and their families and can limit the growth of the Alzheimer's drugs market. The medications used to treat Alzheimer's disease can be costly, limiting some patients access to treatment. This can be especially difficult for patients without private health insurance or who do not qualify for government-funded treatment. The drug approval procedure in the United Kingdom can be lengthy and difficult, delaying the availability of novel Alzheimer's disease treatments. Furthermore, the National Institute for Health and Care Excellence (NICE) cost-effectiveness standards can limit the availability of particular pharmaceuticals. There is still a lot of stigma around Alzheimer's disease, which can make people afraid to seek diagnosis and treatment. Furthermore, there are still numerous misconceptions about the disease and its treatment, which can limit access to care and contribute to the issues that the Alzheimer's drug industry is facing.

Competitive Landscape

Key Players

Abbvie
AstraZeneca
Accord Healthcare
Biogen
Aesica Queenborough
Allen & Hanburys
Daiichi Sankyo Company
Eisai Co.
Eli Lilly and Company
H. Lundbeck A/S
Johnson and Johnson
F. Hoffmann-La Roche AG
Novartis AG
Pfizer

Healthcare Policies and Regulatory Landscape

The UK healthcare policy plays an important role in the availability, accessibility, and affordability of Alzheimer's drugs in the country. The policy framework for Alzheimer's drugs is governed by the National Institute for Health and Care Excellence (NICE) and the National Health Service (NHS). The NHS is responsible for providing healthcare services to the population of the UK, including the provision of Alzheimer's drugs. The NHS provides access to Alzheimer's drugs through the prescription system, where patients receive medication from a healthcare provider, or through hospital clinics. The availability of Alzheimer's drugs through the NHS is subject to cost-effectiveness criteria set by NICE. This means that drugs must be shown to be effective and cost-effective in order to be made available through the NHS.

The UK healthcare policy also places an emphasis on early diagnosis and intervention for Alzheimer's disease. The National Dementia Strategy, launched by the UK government in 2009, aims to improve the diagnosis, treatment, and care of people with dementia, including Alzheimer's disease. The strategy includes measures to improve early diagnosis and access to treatment for people with the disease.

Reimbursement Scenario

The reimbursement scenario for Alzheimer's drugs in the UK is governed by the National Institute for Health and Care Excellence (NICE), which evaluates the clinical and cost-effectiveness of medicines and issues guidance on their use. NICE evaluates drugs based on their clinical effectiveness and their cost-effectiveness. If a drug is deemed clinically effective, NICE will then consider its cost-effectiveness. The cost-effectiveness of a drug is determined by calculating its cost per Quality-adjusted Life Year (QALY) gained. QALY is a measure of the quantity and quality of life gained by a patient from treatment. If the cost per QALY gained is deemed to be within an acceptable range, NICE will recommend the drug for use by the National Health Service (NHS).

Drugs that NICE recommends are made available to patients through the NHS prescription system, where patients receive medication from a healthcare provider, or through hospital clinics.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Alzheimer's Disease Drugs Market Segmentation

By Drug Class (Revenue, USD Bn)

Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine)
N-Methyl-D-Aspartate (NMDA) Receptor Antagonists (Memantine)
Combination Drugs
Others (Lecanemab, Aducanumab)

Drug segmentation is the process of dividing a set of drugs into different categories or classes based on their pharmacological properties, therapeutic uses, and other characteristics. Here, Alzheimer’s Disease Drugs Market is segmented into Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Combination Drugs, and others like (Lecanemab, Aducanumab)

By Distribution Channel (Revenue, USD Bn)

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Route of Administration

Oral
Transdermal
Intravenous

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.